Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.
暂无分享,去创建一个
C. Crews | Y. Qian | K. Coleman | K. Raina | J. Hines | Jing Lu | M. Altieri | Hanqing Dong | Jing Wang | J. Winkler | A. Crew | Kanak Raina
[1] L. Cascione,et al. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs , 2015, Clinical Cancer Research.
[2] Rameen Beroukhim,et al. Sound credit scores and financial decisions despite cognitive aging , 2014, Proceedings of the National Academy of Sciences.
[3] B. Stack,et al. BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo. , 2014, Cancer research.
[4] T. Misteli,et al. Transformation resistance in a premature aging disorder identifies a tumor-protective function of BRD4. , 2014, Cell reports.
[5] Jessica E. Bolden,et al. Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition , 2014, Cell reports.
[6] Paul Shinn,et al. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors , 2014, Proceedings of the National Academy of Sciences.
[7] Jeremy L. Jenkins,et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide , 2014, Nature.
[8] Junwei Shi,et al. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. , 2014, Molecular cell.
[9] D. Felsher,et al. MYC activation is a hallmark of cancer initiation and maintenance. , 2014, Cold Spring Harbor perspectives in medicine.
[10] Zhaohui S. Qin,et al. Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer , 2014, Nature.
[11] B. Nadel,et al. Therapeutic Targeting of c-Myc in T-Cell Acute Lymphoblastic Leukemia (T-ALL) , 2014, Oncotarget.
[12] Dennis L. Buckley,et al. Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system. , 2014, Angewandte Chemie.
[13] Christopher J. Ott,et al. The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins , 2014, Science.
[14] Charles Y. Lin,et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. , 2013, Cancer cell.
[15] R. Vessella,et al. Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer , 2013, Oncotarget.
[16] J. Noel,et al. Abstract C244: Development of the BET bromodomain inhibitor OTX015. , 2013 .
[17] Travis J Cohoon,et al. Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.
[18] David A. Orlando,et al. Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.
[19] K. Stegmaier,et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. , 2013, Cancer discovery.
[20] A. Belkina,et al. BET domain co-regulators in obesity, inflammation and cancer , 2012, Nature Reviews Cancer.
[21] P. Workman,et al. Discovery of small molecule cancer drugs: Successes, challenges and opportunities , 2012, Molecular oncology.
[22] M. Frech,et al. Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter binding , 2012, Leukemia.
[23] S. Lowe,et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.
[24] P. Sandy,et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.
[25] R. Young,et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.
[26] J. Burnett,et al. Current progress of siRNA/shRNA therapeutics in clinical trials , 2011, Biotechnology journal.
[27] William B. Smith,et al. Selective inhibition of BET bromodomains , 2010, Nature.
[28] B. Cravatt,et al. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. , 2010, Future medicinal chemistry.
[29] T. Wirth,et al. Advances in the understanding of MYC‐induced lymphomagenesis , 2010, British journal of haematology.
[30] Toshihiko Ogura,et al. Identification of a Primary Target of Thalidomide Teratogenicity , 2010, Science.
[31] C. Crews,et al. Chemical Inducers of Targeted Protein Degradation* , 2010, The Journal of Biological Chemistry.
[32] J. Aster,et al. BRD–NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells , 2008, Oncogene.
[33] C. Crews,et al. Chemical Approaches to Controlling Intracellular Protein Degradation , 2005, Chembiochem : a European journal of chemical biology.
[34] Michael A. Koldobskiy,et al. Chemical genetic control of protein levels: selective in vivo targeted degradation. , 2004, Journal of the American Chemical Society.
[35] A. Howell,et al. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. , 2004, Best practice & research. Clinical endocrinology & metabolism.
[36] A. Ransick,et al. Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and Degradation* , 2003, Molecular & Cellular Proteomics.
[37] R. Deshaies,et al. Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation , 2001, Proceedings of the National Academy of Sciences of the United States of America.